Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
Recommended as Treatment for Advanced Basal Cell Carcinoma
Curis Eligible for $6 Million Milestone on European Commission Approval
LEXINGTON, Mass., April 26, 2013 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (CRIS), an oncology-focused c... Biopharmaceuticals, Oncology, RegulatoryCuris , Basal Cell Carcinoma, Erivedge, vismodegib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Basal Cell Carcinoma | Cancer & Oncology | Carcinoma | Marketing | Pharmaceuticals | Skin Cancer